What does it do?
Waystar is a growth business that earns money by providing a cloud platform that manages the entire payment cycle between healthcare providers, insurance companies, and patients. Revenue cycle management, which is the industry term for the billing and collection process, is notoriously manual and complex in the United States. Waystar makes money through a mix of predictable subscription fees and volume-based fees charged for every transaction or claim processed. Hospitals and doctors pay for the software because it identifies insurance coverage errors, prevents claim denials, and automates the tedious work of collecting money from patients and insurers.
Where does revenue come from?
The majority of revenue comes from subscription and volume-based fees paid by healthcare providers to manage their financial transactions. For the second quarter of 2026, subscription revenue grew 34 percent to reach $176 million, while volume-based revenue grew 3 percent to $142 million. The company reports revenue across two primary segments: provider revenue, which makes up about 72 percent of the mix, and patient revenue, which accounts for the remaining 28 percent.
Who are its customers?
Waystar serves approximately 30,000 clients representing over 1 million distinct healthcare providers across the United States. Its client base includes 16 of the top 20 institutions on the U.S. News Best Hospitals list, showing its strong position in the large enterprise market. The company recently reported that 1,453 of its clients now contribute over $100,000 in annual revenue, a 15 percent increase from the previous year. Waystar tracks its success through a net revenue retention rate of 108 percent, which proves that existing customers are staying and spending more over time.
What gives it staying power?
Waystar has staying power because its software is integrated into the core financial systems of hospitals, making the cost and risk of switching to a competitor extremely high. Once a hospital connects its clinical data to Waystar's payment engine, moving to a different provider could disrupt cash flow for months.
Where is it headed?
The company is betting its future on agentic AI, which is software that can think and act independently to solve billing problems. By collaborating with Google Cloud, Waystar aims to automate the "silent denials" where insurers take back payments, a move that could significantly increase the financial performance of its clients and solidify Waystar's role as an essential technology partner.
The business is growing at a healthy double-digit pace, with revenue accelerating 18 percent in the most recent quarter. This growth is increasingly driven by high-margin software subscriptions rather than just transaction volume, as subscription revenue jumped 34 percent year-over-year.
Cash generation is a core strength, with the company producing $63.9 million in unlevered free cash flow in the latest quarter. Free cash flow remains consistently positive and tracks closely with adjusted earnings, though heavy investments in AI development and software capitalization have moderately increased capital spending.
Waystar carries a significant but manageable debt load of $1.28 billion, resulting in a net leverage ratio of 2.5 times its earnings. While the debt was used to fund the company's growth and acquisitions, the leverage ratio has trended downward as earnings grow, giving the company more flexibility for its $200 million share repurchase program.
Waystar is a financially strong business that has successfully transitioned to GAAP profitability while maintaining high growth and mid-40s profit margins.
Subscription revenue is growing at 34 percent, far faster than overall revenue, showing that customers are adopting higher-value software modules. This shift toward subscriptions makes the company's income more predictable and less dependent on fluctuating patient visit volumes.
Volume-based revenue grew only 3 percent last quarter, suggesting that the core transaction market is maturing or facing pricing pressure. If this low-growth trend continues, the company will have to rely almost entirely on selling new AI tools to maintain its overall double-digit growth rate.
The healthcare payment software market is valued at roughly $72 billion today and is projected to exceed $150 billion by 2030 as providers digitize their financial offices. Pricing power is structural because billing is too complex for most hospitals to handle alone, creating a "must-have" category for software that improves cash collections. Waystar is a leading specialist in this fragmented market, positioned as the modern cloud alternative to legacy systems and manual labor.
The market is intensely competitive, with barriers to entry built around the difficulty of connecting to thousands of insurance companies. While the industry is consolidating, large providers are increasingly looking for a single platform to handle everything from patient scheduling to final payment. This pressure to consolidate favors large players but forces a constant race on features and automation.
Epic Systems and Oracle Cerner are the most dangerous threats because they already own the software hospitals use to track patients and can bundle billing for free. Optum has a unique advantage because it sees both sides of the payment as part of UnitedHealth Group, giving it superior data on why claims get denied. R1 RCM attacks the market by taking over the entire billing department, which appeals to hospitals looking to shed all administrative staff.
Waystar is holding its ground and gaining share in the cloud-specific segment, evidenced by 15% growth in its large-customer base and high retention rates.
The primary source of protection is high switching costs. Hospitals cannot easily replace Waystar because the platform is integrated into their daily financial operations, and any disruption could delay millions of dollars in payments. This lock-in is proven by the company's 108% net revenue retention rate, which shows that customers not only stay but buy more software over time.
Collectively, the 69% gross margins and mid-40s adjusted EBITDA margins prove that Waystar has a durable cost and efficiency advantage over manual processes. The combination of high margins and stable retention confirms this is a structurally protected software business, not just a commodity service.
The Narrow rating reflects the fact that while switching costs are high, Waystar still faces a captive audience challenge against hospital software giants like Epic. A Wide rating would require Waystar to become the undisputed standard that even Epic users refuse to give up.
The moat is strengthening as the company moves toward an "autonomous revenue cycle" that uses proprietary transaction data to automate tasks that competitors still perform manually.
Delivered 18% revenue growth and raised full-year guidance for 2026.
Authorized $200 million share repurchase while successfully integrating the Iodine Software acquisition.
Institutional investors EQT and CPPIB maintain major stakes, ensuring long-term institutional oversight.
Capital Allocation Track Record
Management has demonstrated a high caliber of judgment by evolving Waystar from a simple billing tool into an AI-powered automation platform. Matthew J. Hawkins has successfully navigated the company through its initial public offering and recent cybersecurity challenges while consistently meeting or beating financial targets. The strategic acquisition of Iodine Software is a clear win, as it provided the clinical data necessary to build more advanced AI tools that competitors struggle to replicate.
The primary governance risk is the high concentration of ownership among institutional investors EQT and CPPIB, which could influence strategy in ways that differ from retail shareholders. While these investors have been stable partners, the recent appointment of a new CFO suggests a phase of transition that warrants monitoring. However, the deep bench of executives and the company's scale provide a credible buffer against key-person risk, as the business is now large enough to operate independently of any single individual.
We expect revenue to grow from $1.3B in FY2026 to $1.8B in FY2031 (~7% CAGR), with EPS growing from $1.66 to $2.86 (~11% CAGR). The cloud-based claims and payment platform is gaining traction as healthcare providers seek to automate manual billing workflows. Fixed software development and administrative costs are spread over a larger base of healthcare transaction volume. EPS grows faster than revenue because the company is benefiting from significant Operating margin expected to reach ~28% by FY2031.
Autonomous billing agents replace manual administrative work. If AI agents can automatically handle insurance appeals, Waystar can charge higher fees while reducing its own support costs.
Deepening clinical data integration via Iodine Software. Combining clinical and financial data allows Waystar to predict payment issues earlier, making the platform indispensable for complex hospital systems.
Market share gains from legacy software providers. As hospitals move to modern cloud systems, Waystar is winning contracts from older, less efficient competitors like NextGen.
Insurance companies build AI tools to block automated claims. If payers create sophisticated AI to reject claims faster than Waystar can appeal them, it would degrade the platform's value.
Hospital software giants bundle billing for zero cost. If Epic or Oracle Cerner improve their integrated billing tools, they could squeeze Waystar out of the large hospital market.
Macroeconomic shift reduces healthcare transaction volumes. A significant decline in elective procedures or patient visits would hurt volume-based revenue and slow overall growth.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Normalized P/E approach based on Waystar's mid-cycle earning power. It fits Waystar because the business recently swung from years of losses to consistent GAAP (standard accounting) profits, meaning a multi-year average of earnings is a better measure of value than one volatile year.
A normalized EPS (earnings per share) of $1.56 multiplied by a 25x multiple gives a per-share fair value of $39. Our 25x multiple sits between legacy software player Oracle (24x) and high-quality fintech Broadridge (26x), and is well above service-heavy peer R1 RCM (18x) because of Waystar's much higher 43% profit margins. We use a normalized EPS of $1.56—the average across the 2025-2028 transition period—to better reflect sustainable earning power as the business matures.
A Forward P/E cross-check (FY2028 EPS $2.09 multiplied by a conservative 18x peer multiple) gives $37.62 — within 4% of our $39 result, confirming the answer. This alternative method uses the single-year profit expected in 2028 and pairs it with the lower multiple currently paid for slower-growing healthcare IT firms. The close agreement between the two methods suggests that even if the market remains skeptical of Waystar's premium quality, the natural growth in earnings should still drive the stock price significantly higher.
We're assuming Waystar can maintain a 43% adjusted EBITDA margin (cash profit before interest and taxes) through 2028. This is reasonable because the company has already achieved this margin in Q2 2026 and its software-led model (69% gross margins) creates natural operating leverage where costs don't rise as fast as sales.
We're assuming the "autonomous revenue cycle" strategy maintains the current 108% net revenue retention rate. This means existing customers are spending 8% more each year; management's focus on agentic AI—software that can automatically appeal insurance denials—is a high-value tool that supports this steady spending growth.
We're assuming the market will eventually value Waystar at a 25x P/E (price-to-earnings) multiple. This is a premium to legacy peers but sits below high-growth software companies, reflecting a balance between Waystar's superior margins and its current high debt levels.
The biggest risk is that Waystar’s high debt load of $1.48B limits its ability to invest in AI as interest costs rise. This could force fair value down toward $28 if investors lower the valuation multiple from 25x to 18x to account for higher financial risk. Watch for "Interest expense, net" growing faster than "Income from operations" in the next quarterly report.
Bear case ($28): Volume-based revenue growth slows below 5% for two consecutive quarters due to hospital industry consolidation; or Interest expense on the $1.48B debt load rises, consuming more than 30% of operating income.
Bull case ($56): Subscription revenue growth accelerates above 20% as the "AltitudeAI" agents are adopted by more than 50% of the client base; or Adjusted EBITDA margins expand toward 48% as the Iodine Software acquisition synergies fully materialize.
Clearthesis wrote this report from 44 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on August 15, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.